Erlotinib in Treating Patients With Barrett Esophagus
Esophageal Cancer - Precancerous Condition
Conditions: official terms
Barrett Esophagus - Esophageal Neoplasms - Precancerous Conditions
Conditions: Keywords
esophageal cancer, Barrett esophagus
Study Type
Study Phase
Phase 1
Study Design
Masking: Open Label, Primary Purpose: Treatment
Name: erlotinib hydrochloride Type: Drug
Name: laboratory biomarker analysis Type: Other
Name: biopsy Type: Procedure
Overall Status
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with Barrett esophagus.
Detailed Description


- To determine if erlotinib hydrochloride can be used as a chemopreventive agent that can cause histologic regression of Barrett esophagus in patients at high risk of developing esophageal cancer associated with high-grade dysplasia.


- To assess whether erlotinib hydrochloride can cause molecular alterations in EGFR, phospho-EGFR, cyclin D1, cdc2, p16, p53, PCNA, COX-2, and ploidy in Barrett esophagus with high-grade dysplasia.

- To establish surrogate markers of chemoprevention in Barrett esophagus with high-grade dysplasia.

- To validate the histologic scoring of Barrett dysplasia developed by our group.

- To evaluate toxicities associated with the use of erlotinib hydrochloride in patients with Barrett esophagus associated with high-grade dysplasia.

OUTLINE: Patients receive oral erlotinib hydrochloride once daily for 3 months. Patients showing no evidence of progression to cancer by esophagogastroduodenoscopy (EGD) with biopsy receive an additional 3 months of treatment. All patients then undergo repeat EGD, biopsy, and determination of molecular markers (i.e., EGFR, phospho-EGFR, cyclin D1, cdc2, p16, p53, PCNA, COX-2, and ploidy).

After completion of study treatment, patients are followed for 30 days.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both

- Diagnosis of Barrett esophagus with high-grade dysplasia

- Refused surgery or other localized therapy for high-grade dysplasia

- No invasive esophageal carcinoma


- ANC ≥ 1,500/mm³

- Platelet count ≥ 100,000/mm³

- Hemoglobin ≥ 10 g/dL

- Bilirubin normal

- AST and ALT < 3 times upper limit of normal (ULN)

- Alkaline phosphatase < 3 times ULN

- No uncontrolled medical condition

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for at least 1 week after completion of study treatment

- Able to swallow tablets or dissolved tablets

- No known hypersensitivity to erlotinib hydrochloride

- No symptoms suggestive of malignancy (e.g., weight loss or vomiting)

- No history of other malignancies

- No uncontrolled medical or psychiatric condition that would preclude treatment under this clinical trial


- See Disease Characteristics

- No prior exposure to erlotinib hydrochloride

- No concurrent antineoplastic or antitumor agents, including chemotherapy, radiotherapy, immunotherapy, or hormonal therapy

- No concurrent investigational agents
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, United States
Status: Recruiting
Contact: Joaquina C. Baranda, MD - 816-861-4700 ext 6708 -
Start Date
July 2007
Kansas City Veteran Affairs Medical Center
National Cancer Institute (NCI)
Record processing date processed this data on July 28, 2015 page